To evaluate the potential role of both p16 expression and 9p21 deletion as prognostic features we investigated a cohort of more than 2,100 breast cancers employing immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH). The gene discussed is CDKN2A; the disease is breast cancer.